Status:
UNKNOWN
Imaging Evaluation of Central Nervous Autoimmune Diseases
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
MS (Multiple Sclerosis)
NMO Spectrum Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people. Neuromyelitis opti...
Eligibility Criteria
Inclusion
- 18-65 years old;
- Nmosd was diagnosed according to wingerchuk standard revised in 2015, MS was diagnosed according to McDonald standard revised in 2017, and 100 normal people were diagnosed;
- In the acute stage, within 1 month of the onset or stable stage, there was no GD enhanced lesion on MRI, and EDSS score had no significant change within 6 months, which was more than 1 month from the last attack;
- MRI examination was complete: baseline, 6 months, 1 year, 2 years;
- Sign informed consent.
Exclusion
- The course of disease was more than 30 years;
- History of brain injury or spinal cord injury;
- History of central nervous system infection or immunodeficiency syndrome;
- HBV, HCV patients, syphilis, HIV-1, HIV-2 patients;
- Suffering from mental illness;
- Pregnant and lactating women or patients planning to conceive within one year;
- Unable to cooperate to complete the follow-up due to geographical or other reasons;
- Patients also participated in other randomized controlled trials.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04822623
Start Date
May 1 2021
End Date
July 1 2022
Last Update
March 30 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.